Profusa to Acquire Diagnostics Firm in $111M Revenue Play
Event summary
- Profusa signs non-binding term sheet to acquire a commercial-stage diagnostics firm with $111M in 2025 revenue.
- Jack Stover appointed Executive Chairman and CEO; Ben Hwang transitions to President role.
- Liviu Goldenberg joins board, bringing 30+ years of tech and manufacturing leadership experience.
- Deal consideration includes 19.99% common stock and convertible preferred shares for Dx Company shareholders.
- $7M in subordinated convertible notes expected to close alongside acquisition.
The big picture
Profusa’s move into diagnostics represents a strategic pivot from biosensing to recurring revenue streams, targeting addiction treatment and pain management markets. The $111M revenue target suggests scale, but integration risks loom large in this high-stakes transformation play. Leadership changes signal a shift toward operational discipline amid rapid growth ambitions.
What we're watching
- Integration Challenges
- How Profusa will merge its biosensing technology with the Dx Company's CLIA-certified labs and diversified provider base.
- Governance Dynamics
- Whether Liviu Goldenberg’s expertise can guide Profusa through this transformative phase while maintaining shareholder focus.
- Execution Risk
- The pace at which Profusa can close the definitive acquisition agreement and secure the necessary financing.
Related topics